Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cryoglobulinemia].

P Cacoub1, D Sène, D Saadoun

  • 1Service de médecine interne II, hôpital la Pitié-Salpêtrière, AP-HP, 83, boulevard de l'hôpital, 75651 Paris cedex 13, France. patrice.cacoub@psl.aphp.fr

La Revue De Medecine Interne
|February 5, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome and prognosis of isolated carotid vasculitis.

Journal of autoimmunity·2024
Same author

[Clinical characteristics and follow-up of 60 patients with recent diagnosis of giant cell arteritis, NEWTON study].

La Revue de medecine interne·2024
Same author

La Revue de medecine interne·2023
Same author

Behçet's disease uveitis.

La Revue de medecine interne·2023
Same author

French recommendations for the management of non-infectious chronic uveitis.

La Revue de medecine interne·2023
Same author

[Neurological involvement of sarcoidosis: current diagnostic and therapeutic strategies].

La Revue de medecine interne·2023
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles

Cryoglobulinemia, immune complexes causing vasculitis, are often linked to Hepatitis C virus. Combination therapy with Peg-interferon-alpha, ribavirin, and rituximab shows promise for treating this condition.

Area of Science:

  • Immunology
  • Hepatology
  • Rheumatology

Background:

  • Cryoglobulinemia involves immune complexes causing systemic vasculitis affecting skin, joints, nerves, and kidneys.
  • Hepatitis C virus is a primary cause; risk factors include female gender, heavy alcohol use, and advanced liver disease.
  • Symptomatic vasculitis correlates with older age, longer infection duration, and specific cryoglobulin characteristics (Type II, IgM kappa, high levels).

Purpose of the Study:

  • To review the understanding and management of cryoglobulinemia and associated systemic vasculitis.
  • To highlight advances in identifying cryoglobulin causes and pathophysiology.
  • To discuss current and emerging therapeutic strategies for cryoglobulinemic vasculitis.

Main Methods:

  • Literature review of cryoglobulinemia, its causes, and treatment outcomes.

Related Experiment Videos

  • Analysis of factors associated with cryoglobulin production and symptomatic vasculitis.
  • Evaluation of treatment efficacy for Peg-interferon-alpha/ribavirin and rituximab.

    • Main Results:

    • Peg-interferon-alpha and ribavirin achieve a 70% response rate for virology and vasculitis.
    • Rituximab shows an 80% response rate in non-responders but has a 42% relapse rate.
    • Cryoglobulin pathophysiology involves complex immune responses, not directly viral action.

    Conclusions:

    • Optimal antiviral therapy (Peg-interferon-alpha/ribavirin) combined with rituximab represents a new therapeutic direction.
    • Multicenter controlled trials are essential to validate new treatment strategies.
    • Further research is needed to improve long-term outcomes and reduce relapse rates.